School of Public Health, Xiamen University, Xiamen, China.
Department of Clinical Laboratory, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
BMJ Open. 2020 Feb 10;10(2):e033917. doi: 10.1136/bmjopen-2019-033917.
Pregnancy in patients with mechanical heart valves (MHVs) is associated with high maternal complications and fetal complications.Anticoagulation treatments serve to decrease their venous clotting risk. Although some anticoagulation regimens have been used for patients during pregnancy with MHVs, no one is definitively superior among different regimens in recent studies. For a better understanding of the clinical treatment which anticoagulation regimen is more effective and safer during the pregnancy in patients with MHVs, a Bayesian network meta-analysis is necessary.
This protocol has been reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. Related studies until April 2019 will be searched in the following databases: PubMed, Embase,SinoMed and the using the OVID interface to search for evidence-based medicine reviews. A clinical trial registry (www.ClinicalTrials.gov) was also searched for unpublished trials. Both experimental studies (randomised clinical trials) and observational studies (cohort studies, case-control studies and case series studies) will be included in this study. Quality assessment will be conducted using Cochrane Collaboration's tool or Newcastle-Ottawa Scale based on their study designs. The primary outcomes of interest will be the frequencies of serious maternal and fetal events. The additional outcomes of interest will be adverse maternal events, mode of delivery and adverse fetal events. Pairwise and network meta-analysis will be conducted using R (V.3.4.4, R Foundation for Statistical Computing, Vienna, Austria) and Stata (V.14, StataCorp). The ranking probabilities will be estimated at each possible rank for each anticoagulation regimen using the surface under the cumulative ranking curve. Statistical inconsistency assessment, subgroup analysis, sensitivity analysis and publication bias assessment will be performed.
Either ethics approval or patient consent is not necessary, because this study will be based on literature. The results of this study will be published in a peer-reviewed journal.
CRD42019130659.
患有机械心脏瓣膜(MHV)的孕妇会出现较高的母体并发症和胎儿并发症。抗凝治疗可降低静脉血栓形成的风险。尽管一些抗凝方案已用于患有 MHV 的孕妇,但最近的研究并未确定不同方案中哪一种方案更具优势。为了更好地了解临床治疗,有必要进行贝叶斯网状荟萃分析,以了解在 MHV 孕妇怀孕期间哪种抗凝方案更有效和更安全。
本方案是根据系统评价和荟萃分析报告的首选报告项目进行报告的。将在以下数据库中检索截至 2019 年 4 月的相关研究:PubMed、Embase、中国生物医学文献数据库和使用 OVID 接口检索循证医学评论。还将在临床试验注册处(www.ClinicalTrials.gov)中搜索未发表的试验。本研究将纳入实验研究(随机临床试验)和观察性研究(队列研究、病例对照研究和病例系列研究)。使用 Cochrane 协作工具或 Newcastle-Ottawa 量表根据研究设计进行质量评估。主要结局指标为严重母婴事件的发生频率。次要结局指标为不良母婴事件、分娩方式和不良胎儿事件。使用 R(V.3.4.4,维也纳奥地利统计计算基金会)和 Stata(V.14,StataCorp)进行成对和网络荟萃分析。使用累积排序曲线下面积估计每个抗凝方案在每个可能等级的排名概率。将进行排名概率评估、亚组分析、敏感性分析和发表偏倚评估。
由于本研究将基于文献,因此不需要伦理批准或患者同意。本研究的结果将发表在同行评议的期刊上。
PROSPERO 注册号:CRD42019130659。